Corbus Pharmaceuticals Holdings, Inc. (0SZI)
LSE 
Summary
0SZI Chart
Corbus Pharmaceuticals Targets HPV-Linked Head and Neck Cancer With CRB-701 Study
Corbus Pharmaceuticals NASDAQ: CRBP executives and oncology specialists used an ASCO-linked discussion to outline the rationale for focusing the company's CRB-701 program on recurrent or metastatic oropharyngeal head and neck cancer, particularly in patients whose disease is associated with human papillomavirus, or HPV.
Corbus Pharmaceuticals Holdings, Inc. (CRBP) Discusses Clinical Data Update From Phase 1/2 Study of CRB-701 Presented at ASCO Transcript
Corbus Pharmaceuticals Holdings, Inc. (CRBP) Discusses Clinical Data Update From Phase 1/2 Study of CRB-701 Presented at ASCO Transcript
How Much Upside is Left in Corbus Pharmaceuticals (CRBP)? Wall Street Analysts Think 318.33%
The mean of analysts' price targets for Corbus Pharmaceuticals (CRBP) points to a 318.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Corbus Pharmaceuticals Holdings, Inc. (0SZI) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Corbus Pharmaceuticals Holdings, Inc. ever had a stock split?
Corbus Pharmaceuticals Holdings, Inc. Profile
| Biotechnology Industry | Healthcare Sector | Yuval Cohen CEO | LSE Exchange | 21833P301 CUSIP |
| US Country | 36 Employees | - Last Dividend | 14 Feb 2023 Last Split | - IPO Date |
Overview
Corbus Pharmaceuticals Holdings, Inc. is a pioneering Biopharmaceutical company engaged in the development of novel therapeutics aimed at defeating serious illnesses. Founded in 2009, the company operates out of Norwood, Massachusetts, showcasing a strong commitment to addressing unmet medical needs through innovative research and development efforts. Corbus is deeply involved in the clinical trial phase of various drug candidates, signifying its active role in transforming scientific insights into impactful medical treatments. Additionally, the company has entered into a strategic licensing agreement with Jenrin Discovery, LLC, leveraging a vast library of compounds and a robust portfolio of patents for the development and commercialization of advanced therapeutic solutions.
Products and Services
- CRB-701 - An antibody-drug conjugate (ADC) currently in Phase I clinical trial. It specifically targets the expression of Nectin-4 on cancer cells, deploying a cytotoxic payload, monomethyl auristatin E (MMAE), to target and eliminate cancer cells.
- CRB-601 - This is an anti-integrin monoclonal antibody aimed at inhibiting the activation of TGFß expressed on cancer cells. Its primary purpose is the treatment of solid tumors, showcasing Corbus' focus on advancing cancer treatment options.
- CRB-913 - A groundbreaking approach to obesity, CRB-913 acts as a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist. This novel therapeutic strategy underscores Corbus' dedication to addressing a wide range of serious health concerns through innovative pharmacological interventions.
